WS Investor
08 Dec 2025, 14:19
Galapagos reports strong phase 2 car-t data in mantle cell lymphoma, despite planned cell therapy wind-down
Galapagos has presented new phase 2 data from its ATALANTA-1 study at ASH 2025, showing its CD19 CAR T-cell candidate GLPG5101 achieved a 100% objective response rate and 96% complete response rate in heavily pretreated relapsed/refractory mantle cell lymphoma. At a median follow-up of nine months, both duration of response and progression-free survival rates were 83%, with 90% of evaluable patients achieving MRD negativity and most maintaining complete remission.
The fresh, early memory-enriched CAR T product is manufactured with a short 7-day vein-to-vein time, which limited dropout to 4% and eliminated the need for bridging therapy. GLPG5101 showed an encouraging safety profile, with high-grade toxicities largely hematologic and no grade ≥3 cytokine release syndrome and only one grade ≥3 ICANS event reported.
Despite the positive data, Galapagos reiterated its intention to wind down its cell therapy activities as announced in October 2025, while continuing ongoing studies and remaining open to potential buyers for all or part of the cell therapy business.
Galapagos has presented new phase 2 data from its ATALANTA-1 study at ASH 2025, showing its CD19 CAR T-cell candidate GLPG5101 achieved a 100% objective response rate and 96% complete response rate in heavily pretreated relapsed/refractory mantle cell lymphoma. At a median follow-up of nine months, both duration of response and progression-free survival rates were 83%, with 90% of evaluable patients achieving MRD negativity and most maintaining complete remission.
The fresh, early memory-enriched CAR T product is manufactured with a short 7-day vein-to-vein time, which limited dropout to 4% and eliminated the need for bridging therapy. GLPG5101 showed an encouraging safety profile, with high-grade toxicities largely hematologic and no grade ≥3 cytokine release syndrome and only one grade ≥3 ICANS event reported.
Despite the positive data, Galapagos reiterated its intention to wind down its cell therapy activities as announced in October 2025, while continuing ongoing studies and remaining open to potential buyers for all or part of the cell therapy business.